Compare Amphastar Pharmaceuticals Inc (AMPH) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Sony Group Corp trades at $23.52 (market cap $139.99B). The key difference: Sony Group Corp is far larger — about 162× Amphastar Pharmaceuticals Inc's market cap, and Sony Group Corp pays a 0.67% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SONY | |
|---|---|---|
Market Cap | $863.95M | $139.99B |
Sector | Health | Technology |
52-Week High | $30.81 | $30.26 |
52-Week Low | $16.87 | $19.32 |
Enterprise Value | $1.26B | $137.89B |
Dividend Yield | — | 0.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Sony stock trades at $23.46, up 1.56% with bullish technical indicators and strong analyst support. The company shows solid revenue growth with $12.96T in 2025 sales and improved profitability, though 2026 projections indicate potential margin pressure. Recent catalysts include the record-breaking Spider-Man film performance and a $6.3B joint venture with TSMC for next-generation image sensors, positioning Sony for continued entertainment and technology leadership.
Sony presents a compelling investment case with strong entertainment franchises and technological innovation, though investors should monitor execution risks in the gaming transition and potential margin compression. Wall Street remains overwhelmingly bullish with 11 buy ratings and a 29.75% upside potential, but the stock faces challenges from currency volatility and competitive pressures in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
